Abrdn Life Sciences Investors (NYSE:HQL) Short Interest Update

Abrdn Life Sciences Investors (NYSE:HQL) was the target of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 19,100 shares, a drop of 10.3% from the March 31st total of 21,300 shares. Based on an average daily volume of 110,600 shares, the short-interest ratio is presently 0.2 days.

Insiders Place Their Bets

In related news, major shareholder Saba Capital Management, L.P. acquired 120,304 shares of the company’s stock in a transaction that occurred on Friday, April 26th. The shares were bought at an average price of $13.00 per share, with a total value of $1,563,952.00. Following the completion of the transaction, the insider now directly owns 3,025,602 shares in the company, valued at $39,332,826. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have acquired a total of 224,993 shares of company stock worth $2,910,910 over the last quarter. Company insiders own 10.06% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Kingsview Wealth Management LLC grew its holdings in Abrdn Life Sciences Investors by 2.5% in the fourth quarter. Kingsview Wealth Management LLC now owns 36,937 shares of the company’s stock valued at $497,000 after purchasing an additional 904 shares during the period. Janney Montgomery Scott LLC boosted its stake in shares of Abrdn Life Sciences Investors by 1.7% in the third quarter. Janney Montgomery Scott LLC now owns 72,249 shares of the company’s stock worth $901,000 after acquiring an additional 1,220 shares during the last quarter. Shaker Financial Services LLC boosted its stake in shares of Abrdn Life Sciences Investors by 2.1% in the third quarter. Shaker Financial Services LLC now owns 66,528 shares of the company’s stock worth $830,000 after acquiring an additional 1,342 shares during the last quarter. Future Financial Wealth Managment LLC acquired a new stake in shares of Abrdn Life Sciences Investors in the first quarter worth approximately $27,000. Finally, Blue Bell Private Wealth Management LLC boosted its stake in Abrdn Life Sciences Investors by 60.4% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 10,125 shares of the company’s stock worth $136,000 after buying an additional 3,811 shares during the last quarter. 32.21% of the stock is currently owned by hedge funds and other institutional investors.

Abrdn Life Sciences Investors Stock Performance

Shares of NYSE:HQL opened at $13.11 on Wednesday. The business has a 50-day moving average price of $13.43 and a 200-day moving average price of $13.12. Abrdn Life Sciences Investors has a 52-week low of $11.34 and a 52-week high of $14.37.

Abrdn Life Sciences Investors Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Thursday, February 22nd were given a dividend of $0.39 per share. This is a boost from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.30. This represents a $1.56 annualized dividend and a yield of 11.90%. The ex-dividend date of this dividend was Wednesday, February 21st.

About Abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.